LPTX insider transaction filings
LEAP THERAPEUTICS, INC. — 49 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2025-07-01. Screen LPTX transaction legs live →
Insider transaction summary — last 90 days
No Form 4 filings for LPTX between 2026-06-24 and 2026-09-22. The table below lists the most recent filings on record.
Recent Form 4 filings — LEAP THERAPEUTICS, INC.
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2025-07-01 | 4 | Baum Jason — Chief Scientific Officer | Holdings only — no transactions reported | EDGAR |
| 2025-07-01 | 4 | O'Mahony John Mark — Chief Manufacturing Officer | Holdings only — no transactions reported | EDGAR |
| 2025-07-01 | 4 | LAWLOR AUGUSTINE — Chief Operating Officer | Holdings only — no transactions reported | EDGAR |
| 2025-04-01 | 4 | Granfield Christine — VP, Head of Reg Affairs/Qual | Option exercise (M): 22,500 · Tax withholding (F): 6,604 @ $0.32 · Option exercise (M): 22,500 (derivative) @ $0 | EDGAR |
| 2025-04-01 | 4 | Baum Jason — Chief Scientific Officer | Option exercise (M): 22,500 · Tax withholding (F): 6,604 @ $0.32 · Option exercise (M): 22,500 (derivative) @ $0 | EDGAR |
| 2025-04-01 | 4 | O'Mahony John Mark — Chief Manufacturing Officer | Option exercise (M): 22,500 · Option exercise (M): 22,500 (derivative) @ $0 | EDGAR |
| 2025-04-01 | 4 | Sirard Cynthia — Chief Medical Officer | Option exercise (M): 22,500 · Option exercise (M): 22,500 (derivative) @ $0 | EDGAR |
| 2025-04-01 | 4 | Mirabelli Christopher — Chairman of the Board, Director | Option exercise (M): 22,500 · Tax withholding (F): 6,672 @ $0.32 · Option exercise (M): 22,500 (derivative) @ $0 | EDGAR |
| 2025-04-01 | 4 | ONSI DOUGLAS E — CEO,CFO,Pres.,GC,Treas.&Sec., Director | Option exercise (M): 32,500 · Option exercise (M): 32,500 (derivative) @ $0 | EDGAR |
| 2025-04-01 | 4 | LAWLOR AUGUSTINE — Chief Operating Officer | Option exercise (M): 22,500 · Tax withholding (F): 7,797 @ $0.32 · Option exercise (M): 22,500 (derivative) @ $0 | EDGAR |
| 2024-11-15 | 4 | ONSI DOUGLAS E — CEO,CFO,Pres.,GC,Treas.&Sec., Director | Option exercise/expiry (X): 2,136 @ $2.82 · Option exercise/expiry (X): 2,136 (derivative) @ $0 | EDGAR |
| 2024-11-15 | 4 | LAWLOR AUGUSTINE — Chief Operating Officer | Option exercise/expiry (X): 2,136 @ $2.82 · Option exercise/expiry (X): 2,136 (derivative) @ $0 | EDGAR |
| 2024-11-15 | 4 | Mirabelli Christopher — Chairman of the Board, Director | Option exercise/expiry (X): 2,136 @ $2.82 · Option exercise/expiry (X): 2,136 (derivative) @ $0 | EDGAR |
| 2024-11-15 | 4 | CAVANAUGH JAMES H — Director | Option exercise/expiry (X): 213 @ $2.82 · Option exercise/expiry (X): 213 (derivative) @ $0 | EDGAR |
| 2024-10-04 | 4 | Granfield Christine — VP, Head of Reg Affairs/Qual | Grant/award (A): 85,000 (derivative) @ $0 | EDGAR |
| 2024-10-04 | 4 | Sirard Cynthia — Chief Medical Officer | Grant/award (A): 85,000 (derivative) @ $0 | EDGAR |
| 2024-10-04 | 4 | Schilsky Richard — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2024-10-04 | 4 | Richard Christian M — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2024-10-04 | 4 | Martin Patricia A. — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2024-10-04 | 4 | O'Mahony John Mark — Chief Manufacturing Officer | Grant/award (A): 85,000 (derivative) @ $0 | EDGAR |
| 2024-10-04 | 4 | Dietz Thomas John — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2024-10-04 | 4 | Baum Jason — Chief Scientific Officer | Grant/award (A): 85,000 (derivative) @ $0 | EDGAR |
| 2024-10-04 | 4 | Mashiach Nissim — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2024-10-04 | 4 | LOSCALZO JOSEPH — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2024-10-04 | 4 | LI WILLIAM — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2024-10-04 | 4 | ONSI DOUGLAS E — CEO,CFO,Pres.,GC,Treas.,&Sec., Director | Grant/award (A): 170,000 (derivative) @ $0 | EDGAR |
| 2024-10-04 | 4 | LAWLOR AUGUSTINE — Chief Operating Officer | Grant/award (A): 85,000 (derivative) @ $0 | EDGAR |
| 2024-10-04 | 4 | Mirabelli Christopher — Director | Grant/award (A): 85,000 (derivative) @ $0 | EDGAR |
| 2024-10-04 | 4 | CAVANAUGH JAMES H — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2024-01-31 | 4 | Dietz Thomas John — Director | Grant/award (A): 30,000 (derivative) @ $0 | EDGAR |
| 2024-01-31 | 4 | Schilsky Richard — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2024-01-31 | 4 | Granfield Christine — VP, Head of Reg Affairs/Qual | Grant/award (A): 85,000 (derivative) @ $0 | EDGAR |
| 2024-01-31 | 4 | Baum Jason — Chief Scientific Officer | Grant/award (A): 85,000 (derivative) @ $0 | EDGAR |
| 2024-01-31 | 4 | Richard Christian M — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2024-01-31 | 4 | O'Mahony John Mark — Chief Manufacturing Officer | Grant/award (A): 85,000 (derivative) @ $0 | EDGAR |
| 2024-01-31 | 4 | Sirard Cynthia — Chief Medical Officer | Grant/award (A): 85,000 (derivative) @ $0 | EDGAR |
| 2024-01-31 | 4 | Martin Patricia A. — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2024-01-31 | 4 | Mashiach Nissim — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2024-01-31 | 4 | LOSCALZO JOSEPH — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2024-01-31 | 4 | LI WILLIAM — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2024-01-31 | 4 | ONSI DOUGLAS E — CEO,CFO,Pres.,GC,Treas.,&Sec., Director | Grant/award (A): 170,000 (derivative) @ $0 | EDGAR |
| 2024-01-31 | 4 | LAWLOR AUGUSTINE — Chief Operating Officer | Grant/award (A): 85,000 (derivative) @ $0 | EDGAR |
| 2024-01-31 | 4 | Mirabelli Christopher — Chairman of the Board, Director | Grant/award (A): 85,000 (derivative) @ $0 | EDGAR |
| 2024-01-31 | 4 | CAVANAUGH JAMES H — Director | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2024-01-30 | 4 | O'Mahony John Mark — Chief Manufacturing Officer | Option exercise (M): 5,000 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2024-01-30 | 4 | Sirard Cynthia — Chief Medical Officer | Option exercise (M): 5,000 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2024-01-30 | 4 | ONSI DOUGLAS E — CEO,CFO,Pres.,GC,Treas.,&Sec., Director | Option exercise (M): 7,500 · Option exercise (M): 7,500 (derivative) @ $0 | EDGAR |
| 2024-01-30 | 4 | LAWLOR AUGUSTINE — Chief Operating Officer | Option exercise (M): 5,000 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2024-01-30 | 4 | Mirabelli Christopher — Chairman of the Board, Director | Option exercise (M): 5,000 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — LEAP THERAPEUTICS, INC.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-09-22 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers 7.01 — Regulation FD Disclosure 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-09-02 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-18 | 8-K | 1.01 — Entry into a Material Definitive Agreement 3.02 — Unregistered Sales of Equity Securities 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-08-12 | 8-K | 2.02 — Results of Operations and Financial Condition 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-07-21 | 8-K | 3.01 — Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing | EDGAR |
| 2026-06-22 | 8-K | 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-26 | 8-K | 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-14 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-10 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2026-03-16 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=LPTX returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →